Q-omics provides the consensus-scored EBLN2 profile across patient tissues and cancer cell-line models. EBLN2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, EBLN2 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, EBLN2 RNA expression shows 19,957 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where EBLN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EBLN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EBLN2 survival associations across molecular data types. EBLN2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EBLN2 RNA expression–survival associations across cancer types. High EBLN2 expression shows unfavorable associations in THCA, LGG and KICH, but favorable associations in HNSC, UCS and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify HNSC as the clearest survival context for EBLN2 RNA expression.
This table summarizes EBLN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EBLN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EBLN2 shows lower tumor expression in THCA and higher tumor expression in KIRC, STAD, KIRP, PRAD and LIHC. The KIRC box plot shows higher EBLN2 RNA expression in tumor versus normal tissue (log2 FC = +0.169, t-test p = .001).
This table shows molecular features associated with EBLN2 in patient tissues and cancer cell lines. In patient samples, EBLN2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, EBLN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
